Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Recursion Pharmaceuticals Inc RXRX

Healthcare Biotechnology
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RXRX)

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

GlobeNewswire 4 days ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

GlobeNewswire 11 days ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

GlobeNewswire 12 days ago

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

GlobeNewswire November 6, 2024

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

GlobeNewswire October 30, 2024

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

GlobeNewswire October 22, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, RVNC, K, RXRX on Behalf of Shareholders

PR Newswire October 15, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, ARC, RXRX on Behalf of Shareholders

PR Newswire October 15, 2024

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI

Accesswire October 11, 2024
View More News ››

Opinion & Analysis (NDAQ:RXRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RXRX)

Tax loss selling

RXRX is selling off in tax loss season. Keep an eye on it for the bottom, accumulate. Looks like  2025 could be the year for results...
Keepdigging - 6 days ago

RXRX RELEASE OPENPHENOM-S/16 IN GOOGLE CLOUDS NOV 12

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden Recursion Pharmaceuticals, Inc. Tue, November 12, 2024...
Humanist - 11 days ago

RXRX / Recursion & Exscientia Shareholders Approv to combine

Recursion and Exscientia Shareholders Approve the Proposed Combination GlobeNewswire · GlobeNewswire Inc. Recursion...
Humanist - 11 days ago

RXRX REPORT 3RD QTR 2024 EARNINGS & BUSINESS UPDATE TDY AMC

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results Recursion Pharmaceuticals Recursion Pharmaceuticals...
Humanist - November 6, 2024

RXRX 1ST PATIENT IN PHASE 2 STUDY/POTENTIAL FIRST-IN-CLASS

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small...
Humanist - October 22, 2024

Recursion Announces Phase 2 Data of REC-994, a First-in-Dise

JUST IN: $RXRX Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral...
whytestocks - September 3, 2024
View more Bullboard ››

Tenet Fintech Group Inc.

Tenet Fintech Group Inc.

Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial ...
View More »